How can we reduce thrombotic and hemorrhagic events in elderly patients with atrial fibrillation?

Life expectancy is rising globally, leading to an expected increase in age-related cardiovascular diseases. Managing cardiovascular disease in older adults is particularly challenging, as these patients often face multimorbidity, polypharmacy, and increased frailty, factors independently associated with poor prognosis and a higher risk of iatrogenic complications.

Atrial fibrillation (AF) is the most common tachyarrhythmia worldwide, with its prevalence projected to reach 15.9 million in the U.S. by 2050 and 17.9 million in Europe by 2060, driven by the progressive aging of the population. AF patients are at high risk of thromboembolism, and oral anticoagulant (OAC) therapy remains the cornerstone of stroke prevention. However, older AF patients often have multiple comorbidities that elevate bleeding risk, making the net clinical benefit of OAC therapy uncertain.

This review aims to outline strategies for balancing ischemic and hemorrhagic risks in this vulnerable population, following the integrated and holistic management pathway, an evidence-based approach proven to improve outcomes in complex and frail AF patients.